[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postmenopause\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postmenopause":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,49,74,98,122,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100539857","prehabilitation-with-resistance-exercise-training-for-breast-cancer-neoadjuvant-therapy-100539857",false,"NCT06309290","Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy","Prehabilitation Based on Resistance-exercise Training in Women With Breast Cancer Undergoing Neoadjuvant Therapy: From Molecular Mechanism to Clinical Benefits","NEO STRONG","Inclusion Criteria:\n\n* Postmenopausal women with breast cancer in stages I, II and III with luminal breast tumor, HER2+ or TNBC\n* Indication for neoadjuvant chemotherapy\n* Candidates for curative breast surgery\n* Body mass index: 18.5 \\\u003CBMI \\\u003C30 kg\u002Fm2\n* Sedentary (does not perform scheduled or planned physical activity ≥ 2 times a week)\n* Willingness to participate in the study and follow the proposed prehabilitation scheme.\n\nExclusion Criteria:\n\n* Present comorbidities that interact with the metabolism and mobility of the muscles of the body and that do not allow the (safe) performance of strength exercises (e.g., debilitating arthritis, all neurological disorders, paralysis, among others).\n* Severe or uncontrolled cardiovascular disease, cardiac ejection fraction less than 50%\n* Previous antineoplastic treatment\n* Use of nutritional supplements (leucine, glutamine, casein, whey protein, fatty acids and creatine).",true,"FEMALE",{"count":20,"type":21},68,"ESTIMATED","INTERVENTIONAL",[24],"NA","Breast cancer stands as the foremost cause of cancer-related deaths among women worldwide, with the highest incidence of any cancer type. The choice of therapeutic interventions hinges upon factors like cancer stage, cell subtype, and tumor size. Consequently, individuals with more aggressive tumors, such as HER+2 and Triple Negative, or larger tumors often undergo neoadjuvant chemotherapy before breast surgery. However, these anticancer treatments come with side effects like cancer-related fatigue, reduced functional capacity, and changes in body composition, notably skeletal muscle atrophy. Skeletal muscle loss correlates with heightened mortality rates, cardiotoxicity, and diminished quality of life, underscoring the need for early therapeutic interventions. One such promising strategy is prehabilitation, which involves resistance-exercise training aimed at bolstering skeletal muscle mass from the outset of the disease, even preceding breast surgery. Resistance-exercise training has shown favorable effects on women undergoing adjuvant therapy or survivors of breast cancer, however, its molecular and clinical effects in women with breast cancer undergoing neoadjuvant therapy are unknown.",[27,28,29,30],"Prehabilitation","Breast Cancer","Postmenopause","Resistance Training",[27,32,33,34,35],"Breast neoplasm","Strength Training","Skeletal muscle","Muscle strength","RECRUITING","2026-06-10",{"date":39,"type":40},"2026-06-12","ACTUAL",{"date":42,"type":40},"2025-01-01",{"date":44,"type":21},"2026-12",{"name":46,"class":47},"Universidad de La Frontera","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":54,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100634014","phase-1-to-evaluate-the-impact-of-smoking-on-pk-after-single-dose-oral-administration-of-gs1-144-tablets--100634014","NCT07534176","To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .","A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants","Inclusion Criteria:\n\n1)40 to 65 years of age (inclusive) at the time of signing the informed consent form (ICF).\n\n2)Trial participants are healthy females who meet any of the following criteria during screening:\n\n1. Consecutive spontaneous amenorrhea ≥ 12 months.\n2. Consecutive spontaneous amenorrhea ≥ 6 months but \\\u003C 12 months, with serum follicle-stimulating hormone (FSH) levels \\> 40 IU\u002FL.\n3. ≥ 6 weeks after bilateral oophorectomy.\n4. History of hysterectomy with preservation of one or both ovaries and FSH levels \\> 40 IU\u002FL.\n\n   3)Body weight ≥ 45 kg, and body mass index (BMI) within the range of 18-28 kg\u002Fm2 (inclusive).\n\n   4)Able to communicate well with the investigator, understand and comply with all study requirements, voluntarily agree to participate in the trial, and understand and voluntarily sign the ICF.\n\n   5)Smoker:smoking ≥ 10 cigarettes per day within 6 months prior to screening, and urinary cotinine level ≥ 1,000 ng\u002FmL at screening. Smokers will be required to continue smoking in designated areas according to their habits during the study.\n\n   6)Non-smoker: no smoking within 6 months prior to screening, and urinary cotinine level \\\u003C 200 ng\u002FmL at screening.\n\n   Exclusion Criteria:\n   1. Known history of hypersensitivity to the investigational drug, any of its excipients, or related formulations; or a history of allergic disorders (including but not limited to asthma, urticaria); or being allergy-prone (e.g., known allergy to two or more substances).\n   2. History or current diagnosis of diseases of the circulatory, digestive, urinary, respiratory, endocrine and metabolic, hematological and lymphatic, immune, psychiatric and neurological, or dermatological systems, and deemed unsuitable for participation by the investigator.\n   3. History of severe infection, serious trauma, or major surgery within 6 months prior to screening, or planning to undergo surgery during the trial.\n   4. Blood donation or blood loss ≥ 400 mL, or receipt of blood transfusion within 3 months prior to screening, or planning to donate blood within 1 month after the end of the trial.\n   5. Use of any prescription medications \\[including but not limited to drugs known to alter hepatic enzyme activity (e.g., glucocorticoids, sex hormones, anticonvulsants, cyclosporine)\\] within 4 weeks prior to screening, or use of any over-the-counter (OTC) medications (including but not limited to herbal medicines, herbal compound prescriptions, health supplements) or vitamin supplements within 2 weeks prior to screening.\n   6. Trial participants with abnormal findings in physical examination, chest X-ray, abdominal and urinary ultrasound, genital ultrasound, thyroid and parathyroid ultrasound, or laboratory tests at screening, which are deemed unsuitable for participation by the investigator.\n   7. During screening or on D-1, any of the following liver function test results as follows: alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≥ 1.5 × upper limit of normal (ULN), or total bilirubin (TBIL) ≥ 1.2 × ULN.\n   8. Abnormal vital signs and deemed unsuitable for participation by the investigator, or systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg during screening.\n   9. Abnormal 12-lead ECG findings and deemed unsuitable for participation by the investigator, or QTcF \\> 470 ms (Fridericia's formula: QTcF = QT\u002FRR0.33, RR = 60\u002Fheart rate) during screening.\n   10. Positive test results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TP-Ab) during screening.\n   11. Participation in another clinical trial within 3 months prior to screening (except for trial participants who did not receive any investigational intervention), or current participation in any other clinical trial.\n   12. Current or past history of drug abuse within 1 year, or positive urine multi-drug test panel.\n   13. Positive alcohol breath test or history of excessive alcohol consumption (defined as \\>14 units of alcohol per week) within 3 months prior to screening (One standard alcohol unit is equivalent to 17.5 mL or 14 g of pure ethanol. Alcohol content is labeled by volume (ABV) for all beverage types. This corresponds approximately to 35 mL of 50% spirits or 350 mL of 5% beer), or unwillingness to abstain from alcohol or any alcohol-containing products during the trial.\n   14. Consumption of food or beverages that may affect drug metabolism (e.g., containing grapefruit, starfruit, or their products) within 48 hours prior to admission.\n   15. Excessive consumption of tea, coffee, or caffeinated beverages (\\>8 cups per day, 1 cup=250 mL) within 3 months prior to screening; or consumption of any food or beverage containing or metabolized to caffeine or xanthine (e.g., coffee, tea, chocolate, cola) within 24 hours prior to admission.\n   16. Pregnant or lactating women, or those who have a clinically significant positive pregnancy test result.\n   17. Poor venous access, a history of difficult venipuncture, intolerance to venipuncture\u002Fintravenous indwelling needle, or needle\u002Fblood phobia.\n   18. Other conditions deemed unsuitable by the investigator.","40 Years","65 Years",{"count":59,"type":21},24,[61],"PHASE1",[29],"2026-05-25",{"date":65,"type":40},"2026-05-27",{"date":67,"type":40},"2026-05-20",{"date":69,"type":21},"2027-02-08",{"name":71,"class":72},"Changchun GeneScience Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":18,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":73},"100624177","oral-antioxidant-therapy-targeted-to-the-mitochondria-for-improving-brain-artery-health-in-postmenopausal-women-100624177","NCT07406243","Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women","Mitochondrial-Targeted Antioxidant Supplementation for Improving Cerebrovascular Function in Postmenopausal Women","Inclusion Criteria:\n\n* Age 60 years or older;\n* Postmenopausal women defined as at least 1 year without menses as self-reported;\n* Estrogen-deficient; no hormone therapies (e.g., estrogen, progesterone, testosterone, DHEA, oral contraceptives, etc.) within the previous 6 months;\n* Ability to provide informed consent;\n* Willing to accept random assignment to condition;\n* Body mass index (BMI) ≤35 kg\u002Fm2;\n* Mini-mental state examination score ≥21;\n* Weight stable in the prior 3 months;\n* Abstinence from antioxidant or CoQ10 therapy for 3 months; and\n* Absence of clinical disease as determined by the physician of record following a medical history and blood chemistries\n\nExclusion Criteria:\n\n* History of uncontrolled hypertension;\n* Currently meeting aerobic exercise guidelines of ≥75 mins\u002Fweek of vigorous or ≥150 mins\u002Fweek of moderate intensity exercise as assessed by Modified Activity Questionnaire;\n* Current smoker;\n* Alcohol dependence or abuse;\n* Other chronic medical conditions; and\n* Subject report of blood donation within 8 weeks prior to enrolling.","60 Years",{"count":83,"type":21},86,[24],"The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \\[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are:\n\nDoes MitoQ improve cerebrovascular function in postmenopausal women?\n\nIf so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries?\n\nResearchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function.\n\nParticipants will:\n\nTake MitoQ (20 mg\u002Fday) or a placebo every day for 3 months\n\nVisit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point\n\nKeep track of symptoms and events during their treatment period to report to the study team",[87,29],"Aging","NOT_YET_RECRUITING","2026-02-06",{"date":91,"type":40},"2026-02-12",{"date":93,"type":21},"2026-04",{"date":95,"type":21},"2030-07",{"name":97,"class":47},"Colorado State University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":18,"minAge":106,"maxAge":57,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":73},"100503165","the-influence-of-hormone-replacement-therapy-and-supervised-exercise-training-on-body-composition-cardiovascular-risk-and-insulin-sensitivity-in-postmenopausal-women-100503165","NCT05831709","The Influence of Hormone Replacement Therapy and Supervised Exercise Training on Body Composition, Cardiovascular Risk and Insulin Sensitivity in Postmenopausal Women","De Invloed Van Hormoonsubstitutietherapie en Gesuperviseerde Training op Lichaamssamenstelling, Cardiovasculair Risico en Insulinegevoeligheid Bij Postmenopauzale Vrouwen","OPERATE","Inclusion Criteria:\n\n* Postmenopausal women (diagnosed by physician) with complaints due to menopause\n* Indication for hormonal substitution therapy (except for the control group)\n* Good general health\n* BMI: 20-30 kg\u002Fm2\n* Only the use of cholesterol-, blood pressure- or\u002Fand thyroid-regulating medication is permitted","45 Years",{"count":108,"type":21},390,[24],"This trial investigates whether supervised training in combination with hormonal substitution therapy has an impact on body composition, cardiovascular risk, risk for dementia, osteoporosis and insulin sensitivity in postmenopausal women.",[29,112],"Menopausal Complaints","2025-11-14",{"date":115,"type":40},"2025-11-18",{"date":117,"type":40},"2023-05-12",{"date":119,"type":21},"2028-12",{"name":121,"class":47},"University Hospital, Ghent",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":18,"minAge":106,"maxAge":57,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":73},"100578589","glylo-supplement-pilot-trial-on-glycation-and-aging-in-postmenopausal-women-100578589","NCT06813261","GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women","A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Trial Investigating the Impact of a Glycation Lowering (GLYLO) Supplement on Geroscience Outcomes in Postmenopausal Women","GRACE","Inclusion Criteria:\n\n1. Adults identified as female at birth with ovaries present (self-report)\n2. Post menopause \\>1y since last menses (self-report)\n3. Aged 45 - 65 y\n4. Anthropometric criteria (either of the following must be met):\n\n   * BMI ≥ 25 kg\u002Fm², based on self-reported weight and height\n   * OR Waist circumference ≥88 cm, based on self-measured values. Participants may provide average home weight measurements over two consecutive days if their BMI at the screening visit is slightly below 25 kg\u002Fm².\n5. HbA1c 5.5- 6.4% (screening measurement)\n6. Able to read and speak English well enough to provide informed consent and understand instructions.\n7. Able to attend in-person visits at The Buck Institute\n\nExclusion Criteria:\n\n1. Surgical menopause (self-report)\n2. Hysterectomy and\u002For ovariectomy (self-report)\n3. Receiving systematic hormone replacement therapy (HRT) (self-report). Use of local vaginal estrogen therapy (e.g., estrogen creams, vaginal tablets, or estrogen rings such as Estring) is permitted.\n4. Currently prescribed or received weight loss medications within the past 6 months or currently enrolled in a defined weight loss program. Weight must be stable (\\> 4%) within the last 3 months.\n5. Regular use of GLYLO, or regular use of a supplement containing any of the ingredients in GLYLO, within the last 3 months.\n6. Diabetes, T1DM or T2DM (self-report and screening tests): Treatment with any hypoglycemic agents (self-report), fasting glucose \\>125 mg\u002FdL (screening test; may reassess once), current use of hypoglycemic drugs for non-diabetic reasons (self-report).\n7. Elevated blood pressure readings (screening test): Resting Systolic Blood Pressure (SBP) ≥180 mmHg or resting Diastolic Blood Pressure (DBP) ≥100 mmHg. If a participant's blood pressure is elevated at the screening visit but not consistent with this threshold, they may provide home blood pressure readings (twice daily for two consecutive days) for the study team to evaluate eligibility.\n8. Psychotropic and\u002For other medications known to significantly impact weight unless on a stable dose for ≥ 6 months (self-report).\n9. Liver enzyme tests (alanine transaminase, aspartate transaminase) (screening test): \\>2 times the laboratory upper limit of normal. Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen).\n10. Immunosuppressive disorders, taking immunosuppressive medications (including oral prednisone \\>10mg\u002Fday and biological immunosuppressants), or receiving chemotherapy.\n11. Active gastrointestinal bleeding, or active bleeding diathesis (or resolved within 6 months prior to randomization) (self-report)\n12. Active peptic ulcer disease (or resolved within 6 months prior to randomization) (self-report)\n13. Active malignancy (or resolved within 6 months prior to randomization), except non-melanoma skin cancer not undergoing treatment (self-report).\n14. Active infection (or resolved within 1 month prior to randomization) (self-report)\n15. Allergy or hypersensitivity to any component of the supplement (self-report)\n16. History of hyperthyroidism or thyroid cancer(self-report), current abnormal thyroid function (blood test at screening).\n17. Cognitive status: Unable to provide informed consent to participate in and safely complete the protocol, as based on the judgment of the investigators (screening visit)\n18. Psychiatric status: any condition that might affect the ability to comply with the protocol in the opinion of the Clinical Investigator or Medical Officer (screening visit)\n19. Active eating disorders (self-report).\n20. Active diagnosis of Gout (self-report)\n21. Any change to prescription medications within 3 months prior to randomization that are judged by the study physician to impact the results of the study (self-report)\n22. No overnight hospitalization within 1 month prior to randomization (self-report)\n23. The presence of a condition or abnormality that in the opinion of the Investigator or Medical Officer would compromise the safety of the patient or the quality of the data",{"count":131,"type":21},30,[24],"The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline.\n\nThis study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.",[29,135,136],"Metabolism","Geroscience",[138,139,140,141,142,143,144],"Dietary supplement","Healthy aging","Women's health","Hormones","Advanced glycation end products (AGEs)","Glycation stress","Metabolic stress","2025-09-04",{"date":147,"type":40},"2025-09-08",{"date":149,"type":40},"2025-04-01",{"date":151,"type":21},"2026-06-30",{"name":153,"class":47},"Buck Institute for Research on Aging",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":18,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":165,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":73},"100585709","resting-energy-expenditure-in-postmenopausal-women-100585709","NCT06905886","Resting Energy Expenditure in Postmenopausal Women","Impact of Menopausal Hormone Therapy on Resting Energy Expenditure in Postmenopausal Women","MenoBOLISM","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Healthy postmenopausal woman\n* Indication for MHT (e.g. climacteric syndrome, osteoporosis, etc.)\n* Body Mass Index (BMI) 18.5 - 29.9 kg\u002Fm2\n* Non smoker\n* Willingness to maintain unchanged dietary habits and the type and frequency of sports activities throughout the entire 6-week study period. I.e. no dietary changes\u002Frestrictions, start of a special exercise program or start of any weight-loss measures are planned during the study period.\n\nExclusion Criteria:\n\n* Pregnancy or Lactation\n* Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)\n* Systemic hormone therapy or hormonal contraception (estrogens, progestogens, androgens) during the study and within 12 weeks prior to study entry\n* Phytotherapeutics for therapy of climacteric syndrome during the study and within 12 weeks prior to study entry\n* Use of psychotropic drugs and other drugs that have an influence on resting energy expenditure during the study and within 12 weeks prior to study entry\n* Substance abuse (e.g. nicotine, alcohol, drugs)\n* Use of appetite suppressants\n* Hypersensitivity or allergy to class of drugs or to any ingredients of the used IMPs (Oestrogel® and Utrogestan®)\n* Contraindication for estradiol or progesterone medication according to swissmedicinfo.ch: Neoplasia of the breast or other sexual organ; Benign or malignant liver tumors; Acute or chronic liver disease; Cholestatic jaundice; Porphyria; Arterial or venous thromboembolic events; Abnormal genital bleeding of unknown cause\n* Use of medication with active ingredients that interact with the metabolization of estradiol or progesterone. For each medication a drug interaction check will be performed: Lexicomp® Drug Interactions, UpToDate®\n* Known or suspected non-compliance due to inability to follow the procedures of the study (e.g. illiteracy, language problems, psychological disorders, dementia, etc.)","18 Years",{"count":164,"type":21},37,"6 Weeks","OBSERVATIONAL","Obesity and its associated comorbidities are rising at an alarming rate, particularly among postmenopausal women. Menopause, characterized by a decline in estradiol and progesterone levels, is often accompanied by weight gain. Fear of this weight gain is a major reason why many women hesitate to initiate or continue menopausal hormone therapy (MHT), with discontinuation often occurring within the first few months. However, scientific evidence on whether MHT influences weight gain remains inconclusive. A Cochrane Review found no significant effect of estrogen or combined estrogen-progestogen therapy on menopause-related weight gain, suggesting that aging and lifestyle changes play a more prominent role.\n\nWhile the effects of estrogen on energy intake have been well-documented, data on its impact on energy expenditure-particularly resting energy expenditure (REE), the largest component of total energy expenditure-are scarce. Several studies suggest that sex hormones may influence REE, as observed in premenopausal women, where REE increases during the luteal phase when estradiol and progesterone levels are high. However, findings on this topic remain inconsistent, and it is unclear whether estrogen or progesterone plays the primary role. Research on the effects of exogenous hormone administration, such as MHT, on REE is extremely limited, with existing studies producing mixed results. Additionally, the potential influence of progestogens on REE has been largely overlooked. Given that a low REE is a strong predictor of weight gain and obesity, understanding the effects of MHT on REE is crucial.\n\nThis observational clinical trial aims to investigate the precise effect of MHT (estradiol + progesterone) on REE in postmenopausal women with an indication for MHT. Secondary objectives include examining MHT's impact on energy intake, physical activity energy expenditure, performance capacity, body composition, core body temperature, serum hormone profiles (luteinizing hormone, follicle-stimulating hormone, estradiol, progesterone), glucose metabolism, fasting blood lipid levels, and miRNA expression (miR-370 and miR-29b, which are involved in lipid and glucose metabolism). Additionally, the study will assess various aspects of subjective well-being and quality of life.\n\nBy addressing the current gaps in scientific knowledge, this study seeks to provide robust evidence on the role of MHT in energy metabolism, potentially reshaping perspectives on its risks and benefits in postmenopausal women.",[29,169,170],"Energy Expenditure","Hormone Replacement Therapy","2025-03-31",{"date":173,"type":40},"2025-04-02",{"date":175,"type":21},"2025-08",{"date":177,"type":21},"2027-02",{"name":179,"class":47},"Insel Gruppe AG, University Hospital Bern"]